Gynofem Healthcare Annual Report | Revenue | Balance Sheet

Gynofem Healthcare and Pharmaceuticals Limited Standalone Balance Sheet (Rs. in thousands).

Gynofem Healthcare and Pharmaceuticals Limited Standalone Profit & Loss Statement (Rs. in thousands).

Gynofem Healthcare and Pharmaceuticals Limited Standalone Cash Flow Statement (Rs. in thousands).

Summary of the Cash Flow Statement for the years 2025 and 2024:

Cash Flow from Operating Activities

The operating activities generated negative cash flow of ₹7,839.95 thousand in FY 2024-25, although this represents a slight improvement compared to the ₹9,354.71 thousand outflow in FY 2023-24. The negative operating cash flow is mainly driven by the loss before tax of ₹17,892.84 thousand, which is significantly higher than the previous year’s loss of ₹4,799.61 thousand. Depreciation of ₹5,223.92 thousand provided a non-cash adjustment that partially reduced the negative impact of losses.

Working capital movements had mixed effects. Trade and other payables increased by ₹6,427.04 thousand, which helped conserve cash, while trade receivables increased by ₹4,181.53 thousand, indicating that more sales remain uncollected. Inventories decreased by ₹2,586.91 thousand, which supported cash flow. Despite these adjustments, the company’s operations still resulted in a substantial cash outflow, reflecting weak operational performance.

Cash Flow from Investing Activities

Investing activities resulted in a cash outflow of ₹1,794.08 thousand in FY 2024-25, compared to a smaller outflow of ₹305.23 thousand in FY 2023-24. The major reason for this increase in outflow was the purchase of plant, property, and equipment worth ₹1,797.52 thousand, suggesting that the company invested in expanding or maintaining its production capacity. Interest income of ₹3.45 thousand provided a minor inflow but had an insignificant effect on overall investing cash flow.

Cash Flow from Financing Activities

Financing activities remained the primary source of cash for the company. During FY 2024-25, the company raised ₹9,413.21 thousand through borrowings, which is nearly the same as ₹9,491.78 thousand raised in FY 2023-24. This indicates that the company is heavily dependent on external financing to support its operations and investments, as operating activities are not generating positive cash flows.

Overall Cash Position

The overall cash position of Gynofem Healthcare and Pharmaceuticals Limited slightly weakened during FY 2024-25. The company recorded a net decrease in cash and cash equivalents of ₹220.82 thousand, compared to a decrease of ₹168.16 thousand in FY 2023-24. As a result, the cash balance declined from ₹628.71 thousand at the beginning of the year to ₹407.89 thousand at the end of the year. This indicates that the company continues to face pressure on its liquidity, though the reduction in cash remains relatively moderate.

Financial ratios of Gynofem Healthcare and Pharmaceuticals Limited.

Summary of the Financial Ratio of Gynofem Healthcare and Pharmaceuticals for the years 2025 and 2024:

Current Ratio:
The current ratio declined from 1.48 in 2024 to 1.08 in 2025, indicating a weakening short-term liquidity position. Although the ratio is still slightly above 1, which means current assets are just sufficient to cover current liabilities, the decrease suggests that the company’s ability to meet short-term obligations has reduced compared to the previous year.

Debt–Equity Ratio:
The debt–equity ratio increased from 0.17 in 2024 to 0.37 in 2025, showing that the company has increased its reliance on borrowed funds. This indicates a higher level of financial leverage and suggests that the company is using more debt to finance its operations, which may increase financial risk if profitability does not improve.

Debt Service Coverage Ratio:
The DSCR improved significantly from -0.27 in 2024 to 144.79 in 2025. This sharp increase indicates that the company has a much stronger ability to meet its debt servicing obligations, possibly due to higher non-cash expenses such as depreciation or changes in earnings before interest and taxes.

Return on Equity:
The return on equity declined from -10.54% in 2024 to -28.15% in 2025, indicating a significant deterioration in shareholders’ returns. The negative value shows that the company incurred losses, which reduced the returns generated from shareholders’ investments.

Inventory Turnover Ratio:
The inventory turnover ratio increased slightly from 7.84 in 2024 to 8.20 in 2025, indicating improved efficiency in managing inventory. A higher ratio suggests that the company is selling and replacing its inventory more frequently, which reflects better inventory management.

Trade Receivables Turnover Ratio:
The trade receivables turnover ratio decreased from 7.05 in 2024 to 6.84 in 2025. This indicates that the company is taking slightly longer to collect payments from customers, which may affect cash flow and working capital management.

Trade Payables Turnover Ratio:
The trade payables turnover ratio increased from 3.95 in 2024 to 4.47 in 2025, suggesting that the company is paying its suppliers more frequently compared to the previous year. This may improve supplier relationships but could also increase short-term cash outflows.

Net Capital Turnover Ratio:
The net capital turnover ratio improved from 9.53 in 2024 to 13.94 in 2025, indicating more efficient utilization of working capital to generate revenue. The increase suggests that the company is generating higher sales relative to its working capital.

Net Profit Ratio:
The net profit ratio declined from -0.21 in 2024 to -0.42 in 2025, indicating that the company’s losses increased during the year. This suggests that expenses have grown faster than revenue, leading to weaker profitability.

Return on Capital Employed:
The return on capital employed decreased from -4.67% in 2024 to -18.06% in 2025, reflecting inefficient utilization of the company’s capital. The negative ratio indicates that the company was unable to generate adequate returns from the capital invested in the business